
Novacyt base_AAQS 2025
Novacyt base_AAQS
4
components_StockPageHeader__3
ALNOV.PA
components_StockPageHeader__4
FR0010397232
components_StockPageHeader__5
A12CFH
pages_kennzahlen_[key]_[isin]__35
Novacyt Aktienanalyse
pages_kennzahlen_[key]_[isin]__1
Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt ist eines der beliebtesten Unternehmen auf Eulerpool.com.pages_dividenden_[isin]_index__2
components_kpi_Savingsplan_0
Andere Kennzahlen von Novacyt
components_SimilarSitesList_0
- Novacyt base_Umsatz
- Novacyt base_Gewinn
- Novacyt base_KGV
- Novacyt base_KUV
- Novacyt base_EBIT
- Novacyt base_Dividende
- Novacyt base_Aktien
- Novacyt base_Marktkapitalisierung
- Novacyt base_Schulden
- Novacyt base_Verbindlichkeiten
- Novacyt base_Eigenkapital
- Novacyt base_AAQS
- Novacyt base_Mitarbeiter
- Novacyt base_ROE
- Novacyt base_ROA
- Novacyt base_ROCE